Kazia Therapeutics (KZIA) Total Non-Current Liabilities (2009 - 2025)
Kazia Therapeutics' (KZIA) quarterly Total Non-Current Liabilities came in at $178697.5 in Q4 2025, down 94.75% YoY from $3.4 million in Q4 2024, and down 9.48% on a QoQ basis from $197405.8 in Q2 2025.
Kazia Therapeutics (KZIA) Total Non-Current Liabilities (2009 - 2025) Analysis & Trends
Kazia Therapeutics (KZIA) has 17 years of Total Non-Current Liabilities data on file, last reported at $178697.5 in Q4 2025.
- Quarterly Total Non-Current Liabilities fell 94.75% year-over-year to $178697.5 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $178697.5 (down 94.75% YoY) and the FY2025 annual result came in at $197405.8, down 94.84% from the prior year.
- Total Non-Current Liabilities declined to $178697.5 in Q4 2025, from $197405.8 in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $9.2 million in Q2 2021 to a low of $178697.5 in Q4 2025.
- A 5-year average of $5.1 million and a median of $5.4 million in 2023 frame the typical range for Total Non-Current Liabilities.
- Annual changes were most pronounced in 2021 — Total Non-Current Liabilities surged 261.49% — and 2025, when it tumbled 94.84%.
- Tracing KZIA's Total Non-Current Liabilities over 5 years: stood at $8.4 million in 2021, then retreated by 16.92% to $7.0 million in 2022, then slipped by 27.76% to $5.1 million in 2023, then slumped by 32.76% to $3.4 million in 2024, then plunged by 94.75% to $178697.5 in 2025.
- The last three Total Non-Current Liabilities figures came in at $178697.5 (Q4 2025), $197405.8 (Q2 2025), and $3.4 million (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 40.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.53 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.88 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.32 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.17 Bn |
| 10 | Kazia Therapeutics | 4.22 Bn | 4.22 Bn | - | 178,697.54 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 178,697.54 |
| Jun 30, 2025 | 197,405.85 |
| Dec 31, 2024 | 3.41 Mn |
| Jun 30, 2024 | 3.83 Mn |
| Dec 31, 2023 | 5.06 Mn |
| Jun 30, 2023 | 5.66 Mn |
| Dec 31, 2022 | 7.01 Mn |
| Jun 30, 2022 | 7.80 Mn |
| Dec 31, 2021 | 8.44 Mn |
| Jun 30, 2021 | 9.17 Mn |
| Dec 31, 2020 | 3.81 Mn |
| Jun 30, 2020 | 2.54 Mn |
| Dec 31, 2019 | 3.52 Mn |
| Jun 30, 2019 | 3.56 Mn |
| Dec 31, 2018 | 3.45 Mn |
| Jun 30, 2018 | 3.82 Mn |
| Jun 30, 2017 | 3.90 Mn |
| Dec 31, 2016 | 3.74 Mn |
| Jun 30, 2016 | 3.87 Mn |
| Dec 31, 2015 | 114,430.73 |